BRIEF

on VALBIOTIS (EPA:ALVAL)

Valbiotis launches an innovative food supplement to fight hypercholesterolemia

Valbiotis, a French company specializing in scientific research and the marketing of food supplements, announces the launch of Valbiotis®PRO Cholesterol in France. This new product, intended for the management of mild to moderate hypercholesterolemia, is based on the patented 100% natural active substance Lipidrive®.

From May, Valbiotis®PRO Cholesterol will be available in pharmacies and on the Valbiotis e-commerce platform. This supplement, the result of ten years of research and development, has demonstrated its effectiveness in significantly reducing LDL cholesterol levels thanks to two large clinical studies. Its good tolerance and absence of side effects position it as a preferred option for cholesterol management.

A specially created sales force and a patient-oriented digital marketing approach will support the marketing of Valbiotis®PRO Cholesterol. The company is also continuing negotiations for possible international licensing agreements, thus underlining its ambition to become a major player in the fight against metabolic disorders causing cardiovascular diseases. The recommended retail price of the product is €39.95 for one month of supplementation.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALBIOTIS news